Plerixafor plus G-CSF in combination with chemotherapy for stem cell mobilization in a pediatric patient with Ewing's sarcoma

Susana Vives, Juan Manuel Sancho, Francisco Almazán, Jordi Juncà, Joan Ramon Grifols, Josep Maria Ribera

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)

Abstract

Some malignant tumors in childhood require high-dose chemotherapy with stem cell support to achieve a cure. In patients heavily pretreated with myelosuppressive chemotherapy or irradiation, granulocyte colony-stimulating factor (G-CSF) may fail to mobilize stem cells from the bone marrow. Based on the experience with lymphoma and myeloma patients in whom peripheral blood-derived stem cell (PBSC) collection following mobilization with G-CSF failed, we successfully employed plerixafor in a 14-year-old female diagnosed with Ewing's sarcoma in early relapse treated with three lines of chemotherapy in whom PBSC could not be mobilized using either G-CSF alone or G-CSF following chemotherapy. No side effects were observed. Plerixafor may be an effective and safe agent for stem cell collection in pediatric patients with solid tumors, although new studies addressed to evaluate its effectiveness and safety are needed. J. Clin. Apheresis 27:260-262, 2012. © 2012 Wiley Periodicals, Inc.
Original languageEnglish
Pages (from-to)260-262
JournalJournal of Clinical Apheresis
Volume27
Issue number5
DOIs
Publication statusPublished - 1 Nov 2012

Keywords

  • CD34+
  • cell collection
  • mozobil
  • solid tumor
  • young patients

Fingerprint

Dive into the research topics of 'Plerixafor plus G-CSF in combination with chemotherapy for stem cell mobilization in a pediatric patient with Ewing's sarcoma'. Together they form a unique fingerprint.

Cite this